

Guillaume Ploussard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5269350/publications.pdf>

Version: 2024-02-01

108
papers

3,470
citations

147726

31
h-index

161767

54
g-index

116
all docs

116
docs citations

116
times ranked

3970
citing authors

#	ARTICLE	IF	CITATIONS
1	Same-day discharge surgery for robot-assisted radical prostatectomy in the era of ERAS and prehabilitation pathways: a contemporary, comparative, feasibility study. <i>World Journal of Urology</i> , 2022, 40, 1359-1365.	1.2	28
2	Managing Discordant Findings Between Multiparametric Magnetic Resonance Imaging and Transrectal Magnetic Resonance Imaging-directed Prostate Biopsy: The Key Role of Magnetic Resonance Imaging-directed Transperineal Biopsy. <i>European Urology Oncology</i> , 2022, 5, 296-303.	2.6	5
3	Impact of Hospital volume on postoperative outcomes after radical prostatectomy: A 5-Year nationwide database analysis. <i>European Urology Focus</i> , 2022, 8, 1169-1175.	1.6	10
4	Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens. <i>BJU International</i> , 2022, 129, 621-626.	1.3	4
5	Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic). <i>World Journal of Urology</i> , 2022, 40, 419-425.	1.2	11
6	A prehabilitation programme implemented before robot-assisted radical prostatectomy improves perioperative outcomes and continence recovery. <i>BJU International</i> , 2022, 130, 357-363.	1.3	8
7	Same-day-discharge Robot-assisted Radical Prostatectomy: An Annual Countrywide Analysis. <i>European Urology Open Science</i> , 2022, 36, 23-25.	0.2	4
8	Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review. <i>World Journal of Urology</i> , 2022, , 1.	1.2	2
9	Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [68Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management. <i>European Urology</i> , 2022, , .	0.9	1
10	Safety and feasibility of same-day discharge laparoscopic radical prostatectomy: a systematic review. <i>World Journal of Urology</i> , 2022, 40, 1367-1375.	1.2	9
11	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. <i>Cancers</i> , 2022, 14, 1781.	1.7	1
12	PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. <i>Journal of Clinical Medicine</i> , 2022, 11, 1734.	1.0	5
13	The current role of MRI for guiding active surveillance in prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 357-365.	1.9	18
14	Overview of the Development and Use of Akt Inhibitors in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 160.	1.0	14
15	Improved recovery after uro-oncology surgery: the critical role of pre- and re-habilitation. <i>World Journal of Urology</i> , 2022, 40, 1287-1287.	1.2	0
16	Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy. <i>European Urology Open Science</i> , 2022, 41, 24-34.	0.2	5
17	Magnetic Resonance Imaging-Targeted Biopsy and Pretherapeutic Prostate Cancer Risk Assessment: a Systematic Review. <i>Progres En Urologie</i> , 2022, 32, 32/6S3-32/6S18.	0.3	0
18	External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2021, 79, 180-185.	0.9	47

#	ARTICLE	IF	CITATIONS
19	MRI-guided active surveillance in prostate cancer: not yet ready for practice. <i>Nature Reviews Urology</i> , 2021, 18, 77-78.	1.9	12
20	Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. <i>BJU International</i> , 2021, 127, 318-325.	1.3	28
21	Same Day Discharge versus Inpatient Surgery for Robot-Assisted Radical Prostatectomy: A Comparative Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 661.	1.0	10
22	The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies. <i>World Journal of Urology</i> , 2021, 39, 3315-3321.	1.2	6
23	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	2.6	23
24	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 80, 549-563.	0.9	53
25	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2021, 80, 531-545.	0.9	21
26	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 4251.	1.7	17
27	A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 6354-6364.	1.3	7
28	The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 206, 507-516.	0.2	22
29	Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4909.	1.0	3
30	A 5-Year Contemporary Nationwide Evolution of the Radical Prostatectomy Landscape. <i>European Urology Open Science</i> , 2021, 34, 1-4.	0.2	5
31	Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie. <i>Cancers</i> , 2021, 13, 6070.	1.7	2
32	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. <i>European Urology Focus</i> , 2020, 6, 1233-1239.	1.6	33
33	Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. <i>World Journal of Urology</i> , 2020, 38, 663-671.	1.2	10
34	Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study. <i>World Journal of Urology</i> , 2020, 38, 1735-1740.	1.2	6
35	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2020, 77, 733-741.	0.9	85
36	Re: Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 393.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery. <i>World Journal of Urology</i> , 2020, 38, 2493-2500.	1.2	20
38	Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies. <i>Urology</i> , 2020, 137, 126-132.	0.5	7
39	Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. <i>Journal of Clinical Medicine</i> , 2020, 9, 3306.	1.0	4
40	Intercenter reproducibility of software-based fusion biopsies for grade group prediction when targeting suspicious MRI lesions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 734.e11-734.e17.	0.8	1
41	Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. <i>Eur Urol</i> 2020;78:304-6. <i>European Urology</i> , 2020, 78, 310-313.	0.9	9
42	MRI Characteristics Accurately Predict Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3841.	1.0	14
43	One-day Prehabilitation Program Before Robotic Radical Prostatectomy in Daily Practice: Routine Feasibility and Benefits for Patients and Hospitals. <i>European Urology Open Science</i> , 2020, 21, 14-16.	0.2	6
44	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. <i>European Urology Oncology</i> , 2020, 3, 739-747.	2.6	31
45	Confirmation by Early Oncologic Outcomes After Surgery of the Accuracy of Intermediate-risk Prostate Cancer Classification Based on Magnetic Resonance Imaging Staging and Targeted Biopsy. <i>European Urology Open Science</i> , 2020, 21, 5-8.	0.2	3
46	Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1962.	1.0	9
47	A combination of enhanced recovery after surgery and prehabilitation pathways improves perioperative outcomes and costs for robotic radical prostatectomy. <i>Cancer</i> , 2020, 126, 4148-4155.	2.0	41
48	Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 386-392.	0.8	4
49	Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction. <i>Journal of Clinical Medicine</i> , 2020, 9, 225.	1.0	33
50	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2020, 78, 138-142.	0.9	55
51	Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. <i>Journal of Urology</i> , 2020, 203, 338-343.	0.2	53
52	Multi-Institutional Assessment of Routine Same Day Discharge Surgery for Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 204, 956-961.	0.2	33
53	Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies. <i>Cancers</i> , 2020, 12, 285.	1.7	12
54	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. <i>World Journal of Urology</i> , 2019, 37, 243-251.	1.2	37

#	ARTICLE	IF	CITATIONS
55	Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies. <i>World Journal of Urology</i> , 2019, 37, 269-275.	1.2	13
56	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in perioperative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	1.3	53
57	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. <i>European Urology</i> , 2019, 75, 506-514.	0.9	188
58	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. <i>European Urology Focus</i> , 2019, 5, 171-178.	1.6	50
59	Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging. <i>Journal of Urology</i> , 2019, 202, 1182-1187.	0.2	25
60	Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. <i>Radiology</i> , 2018, 287, 534-542.	3.6	56
61	Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment. <i>American Journal of Surgical Pathology</i> , 2018, 42, 423-441.	2.1	38
62	Robotic surgery in urology. <i>Current Opinion in Urology</i> , 2018, 28, 153-158.	0.9	46
63	How can we expand active surveillance criteria in patients with low and intermediate risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. <i>BJU International</i> , 2018, 122, 823-830.	1.3	27
64	Kallikreins Panel for Prostate Cancer Aggressiveness Prediction: More Is Not Enough. <i>European Urology Focus</i> , 2017, 3, 100-101.	1.6	0
65	Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. <i>World Journal of Urology</i> , 2017, 35, 1191-1197.	1.2	10
66	Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 35.e15-35.e19.	0.8	5
67	Current practice and access to prostate MR imaging in France. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 1125-1129.	1.8	30
68	Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey. <i>European Urology Focus</i> , 2016, 2, 514-521.	1.6	11
69	What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?. <i>World Journal of Urology</i> , 2016, 34, 617-624.	1.2	15
70	Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0144237.	1.1	9
71	Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey. <i>World Journal of Urology</i> , 2015, 33, 1741-1747.	1.2	6
72	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	0.9	78

#	ARTICLE	IF	CITATIONS
73	Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e1-71.e9.	0.8	62
74	A Combination of Hemostatic Agents May Safely Replace Deep Medullary Suture during Laparoscopic Partial Nephrectomy in a Pig Model. <i>Journal of Urology</i> , 2015, 193, 318-324.	0.2	11
75	Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e1-265.e7.	0.8	14
76	Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling. <i>Archivos Espanoles De Urologia</i> , 2015, 68, 296-306.	0.1	5
77	Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 157-162.	2.0	0
78	Pelvic Lymph Node Dissection During Robot-assisted Radical Prostatectomy: Efficacy, Limitations, and Complications—A Systematic Review of the Literature. <i>European Urology</i> , 2014, 65, 7-16.	0.9	180
79	Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. <i>World Journal of Urology</i> , 2014, 32, 1331-1338.	1.2	23
80	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 120-137.	0.9	277
81	Challenging treatment decision-making in older urologic cancer patients. <i>World Journal of Urology</i> , 2014, 32, 299-308.	1.2	24
82	Impact of the type of ultrasound probe on prostate cancer detection rate and characterization in patients undergoing MRI-targeted prostate biopsies using cognitive fusion. <i>World Journal of Urology</i> , 2014, 32, 977-983.	1.2	8
83	Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. <i>Human Pathology</i> , 2014, 45, 2006-2013.	1.1	5
84	Nephron-Sparing Surgery for Renal Tumors Measuring More Than 7 cm: Morbidity, and Functional and Oncological Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e19-e27.	0.9	31
85	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	0.9	125
86	Editorial Comment. <i>Journal of Urology</i> , 2014, 191, 637-637.	0.2	0
87	Predictive Factors of Oncologic Outcomes in Patients Who do not Achieve Undetectable Prostate Specific Antigen after Radical Prostatectomy. <i>Journal of Urology</i> , 2013, 190, 1750-1756.	0.2	44
88	Robot-assisted laparoscopic partial nephrectomy: Early single Canadian institution experience. <i>Canadian Urological Association Journal</i> , 2013, 7, 348.	0.3	14
89	Triptorelin in the management of prostate cancer. <i>Future Oncology</i> , 2013, 9, 93-102.	1.1	24
90	The Risk of Upstaged Disease Increases with Body Mass Index in Low-Risk Prostate Cancer Patients Eligible for Active Surveillance. <i>European Urology</i> , 2012, 61, 356-362.	0.9	28

#	ARTICLE	IF	CITATIONS
91	SEMINAL VESICLE INVASION: WHAT IS THE BEST ADJUVANT TREATMENT AFTER RADICAL PROSTATECTOMY?. BJU International, 2012, 109, 531-532.	1.3	0
92	Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification. Urology, 2011, 78, 607-613.	0.5	55
93	Low pretreatment total testosterone (3Ång/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU International, 2011, 107, 1400-1403.	1.3	49
94	Prostate Cancer Antigen 3 Score Accurately Predicts Tumour Volume and Might Help in Selecting Prostate Cancer Patients for Active Surveillance. European Urology, 2011, 59, 422-429.	0.9	136
95	The Contemporary Concept of Significant Versus Insignificant Prostate Cancer. European Urology, 2011, 60, 291-303.	0.9	267
96	The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22. American Journal of Cancer Research, 2011, 1, 498-507.	1.4	3
97	Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer. BJU International, 2010, 106, 86-90.	1.3	21
98	Oncologic Outcome after Extraperitoneal Laparoscopic Radical Prostatectomy: Midterm Follow-up of 1115 Procedures. European Urology, 2010, 57, 267-273.	0.9	52
99	The prognostic significance of bladder neck invasion in prostate cancer: is microscopic involvement truly a T4 disease?. BJU International, 2010, 105, 776-781.	1.3	8
100	Robot-assisted extraperitoneal laparoscopic radical prostatectomy: experience in a high-volume laparoscopy reference centre. BJU International, 2010, 105, 1155-1160.	1.3	32
101	The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number. BJU International, 2010, 106, 1293-1297.	1.3	10
102	Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. Prostate Cancer and Prostatic Diseases, 2010, 13, 97-101.	2.0	8
103	Urine biomarkers in prostate cancer. Nature Reviews Urology, 2010, 7, 101-109.	1.9	102
104	Prognostic Value of Loss of Heterozygosity at Chromosome 9p in Non-muscle-invasive Bladder Cancer. Urology, 2010, 76, 513.e13-513.e18.	0.5	15
105	Pathological Findings and Prostate Specific Antigen Outcomes After Radical Prostatectomy in Men Eligible for Active Surveillance—Does the Risk of Misclassification Vary According to Biopsy Criteria?. Journal of Urology, 2010, 183, 539-545.	0.2	78
106	The Role of Biopsy Core Number in Selecting Prostate Cancer Patients for Active Surveillance. European Urology, 2009, 56, 891-898.	0.9	58
107	Extensive Biopsies and Transurethral Prostate Resection in Men With Previous Negative Biopsies and High or Increasing Prostate Specific Antigen. Journal of Urology, 2009, 182, 1342-1349.	0.2	12
108	Local Recurrence After Nephron-Sparing Surgery in von Hippel-Lindau Disease. Urology, 2007, 70, 435-439.	0.5	40